Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
rct · Level I
Where this comes from
- Record sourced from PubMed, PMID 33328324.
- Also identified by DOI 10.1212/WNL.0000000000011275.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To investigate the effects of siponimod on cognitive processing speed in patients with secondary progressive (SP) multiple sclerosis (MS), by means of a predefined exploratory and post hoc analysis of the Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) study, a randomized controlled trial comparing siponimod and placebo. EXPAND was a double-blind, placebo-controlled phase 3 trial involving 1,651 patients with SPMS randomized (2:1) to either siponimod 2 mg/d or placebo. Cognitive function was assessed with the Symbol Digit Modalities Test (SDMT), Paced Auditory Serial Addition Test (PASAT), and Brief Visuospatial Memory Test-Revised (BVMT-R) administered at baseline, 6-month intervals, and end of treatment. Between-group differences in mean change from baseline in SDMT scores were significantly better in siponimod- vs placebo-treated patients at month 12 (difference 1.08 [95% confidence interval 0.23-1.94]; <i>p</i> = 0.0132), month 18 (1.23 [0.25-2.21); <i>p</i> = 0.0135), and month 24 (2.30 [1.11-3.50]; <i>p</i> = 0.0002). Siponimod-treated patients were at significantly lower risk for having a 4-point sustained decrease in SDMT score (hazard ratio [HR] 0.79 [0.65-0.96]; <i>p</i> = 0.0157), while their chance for having a 4-point sustained increase in SDMT score was higher (HR 1.28 [1.05-1.55]; <i>p</i> = 0.0131). PASAT and BVMT-R scores did not differ significantly between the 2 treatment groups (all <i>p</i> > 0.28). Siponimod had a significant benefit on SDMT in patients with SPMS. Siponimod-treated patients were at significantly lower risk for having a ≥4-point decrease in SDMT score and had a significantly higher chance for having a ≥4-point increase in SDMT score, a magnitude of change accepted as clinically meaningful. NCT01665144. This study provides Class II evidence that, for patients with SPMS, siponimod had a significant benefit on cognitive processing speed.
Medical subject headings
- Azetidines
- Benzyl Compounds
- Cognition
- Multiple Sclerosis, Chronic Progressive
- Sphingosine 1 Phosphate Receptor Modulators